Strides Pharma’s arm SPIAG to acquire Swiss firm Sandoz’s generics portfolio for $12-M

Strides Pharma International AG (SPIAG), a step-down subsidiary of publicly listed, Bengaluru-based Strides Pharma Science, is to acquire a portfolio of branded generic products across Sub-Saharan Africa (SSA) from Switzerland-based Sandoz AG and its group entities for USD 12 million, funded through internal accruals.The acquired portfolio spans four markets: West Africa (10 countries), Ghana, Nigeria, and Kenya, and includes brands in the anti-infective, cardiovascular, and dermatology therapeutic segments. Several products within this portfolio individually generate annual sales exceeding USD 1 million. The acquisition is expected to double Strides Pharma’s presence in the region.